MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer

BACKGROUND: Resistance to endocrine therapy is a major clinical challenge in the management of oestrogen receptor (ER)-positive breast cancer. In this setting, p53 is frequently wildtype and its activity may be suppressed via upregulation of its key regulator MDM2. This underlies our rationale to ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Portman, Neil, Milioli, Heloisa H., Alexandrou, Sarah, Coulson, Rhiannon, Yong, Aliza, Fernandez, Kristine J., Chia, Kee Ming, Halilovic, Ensar, Segara, Davendra, Parker, Andrew, Haupt, Sue, Haupt, Ygal, Tilley, Wayne D., Swarbrick, Alex, Caldon, C. Elizabeth, Lim, Elgene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425060/
https://www.ncbi.nlm.nih.gov/pubmed/32787886
http://dx.doi.org/10.1186/s13058-020-01318-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425060/
https://www.ncbi.nlm.nih.gov/pubmed/32787886
http://dx.doi.org/10.1186/s13058-020-01318-2

Ejemplares similares